Navigation Links
Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
Date:11/20/2007

ST. JOSEPH, Mich., Nov. 20 /PRNewswire/ -- GeneGo, Inc., the leading provider of databases, software and services in systems biology, announced today that Utrecht University will be using MetaDrug in their prestige master program for drug innovation. MetaDrug is designed for predicting biological effects such as indications, toxicity and off-target effects for new compounds structures. Its content includes xenobiotics with known activity, endogenous metabolites and reactions, as well as pathways, networks and diseases which are important for knowledge-based drug discovery. Our integration to Elsevier MDL's Discovery Gate also helps find more information about the compounds of interest in patent databases and clinical trial databases.

"Our research students of drug innovation should learn to see the big picture as soon as possible, in order to become effective drug researchers. MetaDrug is state-of-the-art, but still very accessible to the novice user," said Dr Ed Moret. "We really like the support and training they have offered to our students."

"GeneGo is very serious about including MetaDrug in academic environments especially for teaching," said Julie Bryant, Vice President of Business Development for GeneGo. "Academia pushes the limits of MetaDrug which allows us to further adapt it for new areas of medicinal chemistry and they publish new applications that we may not even have thought of using it in such a way."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in t
'/>"/>

SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
2. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
3. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
6. University of Leicester scientists discover technique to help friendly bacteria
7. MichBio Announces Student Career Day at Michigan State University
8. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
9. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
10. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
11. McGill University Purchases GenVaults Personal Archive System to Manage Rare Cancer Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... deicing film for radar domes have now refined the ... , The new work by Rice chemist James ... windshields to skyscrapers free of ice and fog while ... The technology was introduced this month in the American ... , The material is made of graphene nanoribbons, ...
(Date:9/16/2014)... MILLBROOK, N.Y. , Sept. 16, 2014  Donald Fresne, ... the appointment of Stephan Vagner , PhD to its ... the University of Toulouse, France , performed ... Germany , and at Inserm, the French institute of ... Inserm and works both at the Curie Institute, Orsay, ...
(Date:9/16/2014)... Md. , Sept. 16, 2014   ... biotechnology company developing novel anti-infective biologic and drug ... and diseases, announced today the completion of the Company,s ... which highlighted its irritable bowel syndrome (IBS) ... constipation-predominant IBS (C-IBS). In the keynote ...
(Date:9/16/2014)... 16, 2014  LABSCO, the leading specialty sales ... hospitals, physician office laboratories and alternate healthcare settings ... 2014, it will serve as Siemens Healthcare Diagnostics, ... and as a semi-exclusive sales distributor in specified ... United States . LABSCO will be ...
Breaking Biology Technology:Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Beckman Coulter, Inc. (NYSE: BEC ), ... that simplify, automate and innovate complex biomedical testing, announced ... results. For the fourth quarter, total revenue was ... Diagnostics customers, partially offset by a decline in Life ...
... N.J., Feb. 9 Pharmasset, Inc. (Nasdaq: ... committed to discovering, developing and commercializing novel drugs ... financial results for the fiscal quarter ended December ... million during each of the quarters ended December ...
... Solutia Inc. (NYSE: SOA ) today,announced that Jeffry ... Deutsche Bank Small and Mid Cap Conference at 3:20 p.m.,Eastern ... A live webcast,of the presentation and a replay will be ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081029/AQW096LOGO ) , ...
Cached Biology Technology:Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 2Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 3Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 4Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 5Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 6Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 7Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 8Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 9Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 10Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 11Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 12Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 13Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 14Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 15Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 16Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 17Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 18Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 19Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 20Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 21Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 22Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 23Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 24Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 25Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 26Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 27Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 28Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 29Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 30Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 31Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 32Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals 33Pharmasset Reports Fiscal First Quarter 2009 Financial Results 2Pharmasset Reports Fiscal First Quarter 2009 Financial Results 3Pharmasset Reports Fiscal First Quarter 2009 Financial Results 4
(Date:9/16/2014)... This news release is available in Spanish . ... light on mitosis. The study published in the Journal ... molecules and is essential for proper cell division , At ... and dividing. This is the mechanism by which the body ... It involves a fairly complex process known as "mitosis", during ...
(Date:9/16/2014)... spilled 11 million gallons of oil into Alaska,s Prince ... oil spill in the Gulf of Mexico in 2010. ... of Consumer Research , news coverage of environmental disasters ... changes in the way fossil fuels are used. , ... these two events helped to resolve many of the ...
(Date:9/16/2014)... , Sept. 16, 2014  Valencell, Inc., a leader ... as one of 18 "Showcase Companies" representing ... the annual CED Tech Venture Conference on September 16-17 ... Convention Center in Raleigh, North Carolina ... lead a discussion during the "Digital Health Spotlight Sector" ...
Breaking Biology News(10 mins):Unraveling cell division 2Unraveling cell division 3Exxon Valdez 2014: Does media coverage of manmade disasters contribute to consumer complacency? 2Valencell, Inc. Selected as 'Showcase Company' at CED Tech Venture Conference 2014 2
... reasons for mass strandings of whales and dolphins, in ... themselves up onto a beach, apparently intentionally. Recent genetic ... play a role in these enigmatic and often fatal ... regarding the reason for strandings is that "care-giving behavior," ...
... prairie around Alberta,s Drumheller area was once a lush ... inland sea, with loads of wetlands inhabited by dinosaurs, ... changed about 71-million-years ago, according to a new study ... at the University of Calgary. The researchers, calculations show ...
... of the Deadliest Pathogens , Francisella tularensis , ... pathogens in existence, is considered a potential biological weapon because ... infectivity and lethality in humans. While a live attenuated ... have been unable to understand the basis for its attenuated ...
Cached Biology News:Oh mother, where art thou? 2Oh mother, where art thou? 3Dinosaur-era climate change study suggests reasons for turtle disappearance 2News tips from the journal mBio®, volume 4, issue 1 2
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Shh Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
... to Asparagine synthetase ( Abpromise ... Antigen: ... in the C-terminus of Human ... Entrez GeneID: 440 ...
Biology Products: